Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group announced board-level administrative changes, with joint company secretary, authorized representative and Hong Kong process agent Mr. Lee Leong Yin resigning effective May 15, 2026 due to personal work arrangements. The company emphasized that Mr. Lee has no disagreement with the board and that his departure raises no issues requiring attention from shareholders or the Stock Exchange.
To ensure continuity in governance and regulatory compliance, the board appointed Ms. Zeng Zhao as joint company secretary, authorized representative and Hong Kong process agent from the same date. Zeng, a senior manager at Tricor Services Limited with over a decade of corporate secretarial experience and the requisite professional qualifications under Hong Kong listing rules, will serve alongside existing officers, signaling a smooth transition in the company’s compliance and corporate governance functions.
The board also clarified the updated composition of its senior administrative roles, with Ms. Zhong Shengli and Ms. Zeng serving as joint company secretaries and Ms. Sun Yuan and Ms. Zeng acting as authorized representatives and process agents. These changes reinforce the company’s adherence to Hong Kong regulatory requirements and are expected to have limited operational impact while maintaining stable oversight for investors and other stakeholders.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a Hong Kong-listed pharmaceutical company focused on the research, development, manufacturing and commercialization of prescription medicines. The group targets key therapeutic areas in China and international markets, operating within a highly regulated environment that emphasizes robust corporate governance and compliance with listing rules.
Average Trading Volume: 9,452,595
Technical Sentiment Signal: Buy
Current Market Cap: HK$216.5B
See more insights into 3692 stock on TipRanks’ Stock Analysis page.